A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

To join this study, children and young people must be between 1 and 17 years old and have a clear diagnosis of systemic juvenile idiopathic arthritis (sJIA). They need to have at least two joints that are currently swollen or painful.

There are also some reasons why someone might not be able to join. For example, if they have other specific types of arthritis, a history of certain serious infections, or other autoimmune conditions not related to sJIA, they wouldn't be able to take part. Also, if they have certain conditions like active tuberculosis or recent problems with a serious immune system reaction called Macrophage Activation Syndrome, they won't be eligible.

The study team will carefully check each potential participant's medical history to make sure the study is a good fit for them and that it's safe for them to take part.

If you decide to take part in this study, your child will either receive the study medicine, baricitinib, or in some cases, an existing treatment called tocilizumab. The study is divided into two groups, and the doctors will choose which group is best for your child based on their medical history. You and your child will have regular visits to the clinic so that doctors can check their progress and how they are responding to the medication. This will involve physical examinations, blood tests, and discussions about any symptoms or side effects.

These visits are important for the doctors to make sure the medicine is working and that your child is safe. The full duration of the study will be explained in detail by the study team, and they will tell you exactly what to expect at each appointment, including how long each visit might take and what procedures are involved.